Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
Xun Wang, Xiaoyu Zhao, Jieyu Song, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 477-481
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

SARS-CoV-2 Omicron variant: recent progress and future perspectives
Yao Fan, Xiang Li, Lei Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 484
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2969-2976
Open Access | Times Cited: 301
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 189-199
Open Access | Times Cited: 284
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Rekha Khandia, Shailja Singhal, Taha Alqahtani, et al.
Environmental Research (2022) Vol. 209, pp. 112816-112816
Open Access | Times Cited: 283
Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
Jingwen Ai, Xun Wang, Xinyi He, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1077-1083.e4
Open Access | Times Cited: 171
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112443-112443
Open Access | Times Cited: 154
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
Shuai Xia, Lijue Wang, Yun Zhu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 137
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
John P. Evans, Cong Zeng, Panke Qu, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 8, pp. 1093-1102.e3
Open Access | Times Cited: 134
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 118
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
Panke Qu, Kai Xu, Julia N. Faraone, et al.
Cell (2024) Vol. 187, Iss. 3, pp. 585-595.e6
Open Access | Times Cited: 111
Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review
Chao Wang, Bei Liu, Sihui Zhang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 102
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
Kaiming Tao, Philip L. Tzou, Sergei L. Kosakovsky Pond, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 77
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 77
Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants
Panke Qu, Kai Xu, Julia N. Faraone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 46
Omicron variant: Current insights and future directions
Rashmi Rana, Ravi Kant, Rohit Singh Huirem, et al.
Microbiological Research (2022) Vol. 265, pp. 127204-127204
Open Access | Times Cited: 69
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, et al.
Metabolism Open (2022) Vol. 14, pp. 100180-100180
Open Access | Times Cited: 68
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Hao Zhou, Michelle Møhlenberg, Jigarji Chaturji Thakor, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 68
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 43
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
Lidong Wang, Michelle Møhlenberg, Pengfei Wang, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 70, pp. 13-25
Open Access | Times Cited: 33
Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
Xun Wang, Shuai Jiang, Shujun Jiang, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster
Xun Wang, Shujun Jiang, Wentai Ma, et al.
Cell Host & Microbe (2023) Vol. 32, Iss. 1, pp. 25-34.e5
Open Access | Times Cited: 28
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Xiaoyu Zhao, Tianyi Qiu, Xiner Huang, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 15
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3
Yuanchen Liu, Xiaoyu Zhao, Jialu Shi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 10
Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
Zhifei Chen, Fangqin Xie, Hairong Zhang, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top